SCHEMBL19283725

SCHEMBL19283725

O=C(C(Nc1nc2ccccc2[nH]1)c1cccc(C(F)(F)F)c1)N1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ITGA5 P08648 1/20 0.48
▸ ITGB6 P18564 1/20 0.48
▸ ITGB8 P26012 1/20 0.48
▸ KLRK1 P26718 4/20 0.47
▸ MICA Q29983 4/20 0.47
▸ RAET1L Q5VY80 3/20 0.47
▸ MTOR P42345 1/20 0.45
▸ PHGDH O43175 2/20 0.42
▸ LPAR2 Q9HBW0 1/20 0.40
▸ RAF1 P04049 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ TRPV4 Q9HBA0 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.39
▸ TEAD4 Q15561 1/20 0.39
▸ F2 P00734 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283810 0.93 KLRK1 (0.53) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283862 0.93 KLRK1 (0.52) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821288 0.93 KLRK1 (0.52) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821319 0.91 ITGA5 (0.49) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821297 0.90 TACR1 (0.48) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821304 0.90 HRH4 (0.49) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821293 0.89 ITGA5 (0.46) ITGA5ITGB6ITGB8KLRK1MICA
Iodide SCHEMBL19283626 0.88 ITGA5 (0.46) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283627 0.88 ITGA5 (0.46) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283678 0.85 ITGA5 (0.44) ITGA5ITGB6ITGB8KLRK1MICA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US claimed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US claimed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN claimed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP claimed
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed
EP-3419973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2019-01-02 — — EP disclosed
WO-2017144183-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 ITGA5 3161/4885ITGB6 3120/4885ITGB8 3935/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 ITGA5 2293/4885ITGB6 2913/4885ITGB8 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback